The structure and outcomes of a hiv postexposure prophylaxis program in a high hiv prevalence setup in Western Kenya

Journal of Acquired Immune Deficiency Syndromes

Volumn 51, Issue 1, 2009, Pages 47-53

  Siika, Abraham M ^a,b,c   Nyandiko, Winston M ^a,b   Mwangi, Ann ^b,d   Waxman, Michael ^b,d   Sidle, John E ^a,b,c   Kimaiyo, Sylvester N ^a,b   Wools Kaloustian, Kara ^a,b,c  

^a MOI TEACHING AND REFERRAL HOSPITAL   (Kenya)

^b Academic Model for the Prevention and Treatment of HIV ^*  (Kenya)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BROWN UNIVERSITY   (United States)

Author keywords

Health care worker; HIV; Postexposure prophylaxis; Sexual assault

Indexed keywords

ANTIRETROVIRUS AGENT; DOXYCYCLINE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; LAMIVUDINE; LEVONORGESTREL; LOPINAVIR; NORFLOXACIN; RECOMBINANT HEPATITIS B VACCINE; RITONAVIR; RNA POLYMERASE; SPECTINOMYCIN; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KENYA; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL EXPOSURE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL;

ADULT; ALGORITHMS; ANTI-HIV AGENTS; CHILD; FEMALE; HEALTH PERSONNEL; HIV; HIV INFECTIONS; HIV SEROPREVALENCE; HUMANS; KENYA; MALE; NATIONAL HEALTH PROGRAMS; OCCUPATIONAL EXPOSURE; RISK FACTORS; RNA, VIRAL;

EID: 67651174772     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318198a96a     Document Type: Article

References (36)

1. Centers for Disease Control and Prevention. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep. 2005;54(RR-9):1-24.
2. Bell DM. Occupational risk of human immunodeficiency virus infection in health-care workers: an overview. Am J Med. 1997;102:9-15.
3. Centers for Disease Control and Prevention. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep. 2005; 54(No. RR-2):1-28.
4. UNAIDS. AIDS Epidemic Update, December 2007. Geneva: UNAIDS; 2007 Available at: http://data.unaids.org/pub/EPISlides/2007/2007-epiupdate-en.pdf. Accessed March 26, 2009.
5. Grant AD, Djomand G, Smets P, et al. Profound immunosuppression across the spectrum of opportunistic disease among hospitalized HIVinfected adults in Abidjan, Cô te d'Ivoire. AIDS. 1997;11:1357-1364.
6. Onyemelukewe GC, Musa BO. CD4+ and CD8+ lymphocytes and clinical features of HIV seropositive Nigerians on presentation. Afr J Med Med Sci. 2002;31:229-233.
7. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342:921-929.
8. Kiragu K. On the Frontlines: Kenyan Health Workers Confront HIVRelated Challenges at Work and Home. The Population Council Inc Horizons report: HIV/AIDS operations research; June 2006. Available at: http://www.popcouncil. org/horizons/newsletter/horizons(12)-4.html. Accessed March 25, 2009.
9. Gounden YP, Moodley L. Exposure to human immunodeficiency virus among healthcare workers in South Africa. Int J Gynaecol Obstet. 2000; 69:265-270.
10. Tarantola A, Koumare A, Rachline A, et al. A descriptive, retrospective study of 567 accidental blood exposures in healthcare workers in three West African countries. J Hosp Infect. 2005;60:276-282.
11. Palmer CM, McNulty AM, D'Este C, et al. Genital injuries in women reporting sexual assault. Sex Health. 2004;1:55-159.
12. Kawsar M, Anfield A, Walters E, et al. Prevalence of sexually transmitted infections and mental health needs of female child and adolescent survivors of rape and sexual assault attending a specialist clinic. Sex Transm Infect. 2004;80:138-141.
13. Olley BO, Abrahams N, Stein DJ. Association between sexual violence and psychiatric morbidity among HIV positive women in South Africa. Afr J Med Med Sci. 2006;35(Suppl):143-147.
14. Worthington MG, Ross JJ, Bergeron EK. Posttraumatic stress disorder after occupational HIV exposure: two cases and a literature review. Infect Control Hosp Epidemiol. 2006;27:215-217.
15. Shih CC, Kaneshima H, Rabin L, et al. Postexposure prophylaxis with zidovudine suppresses human immunodeficiency virus type 1 infection in SCID-hu mice in a time-dependent manner. J Infect Dis. 1991;163: 625-627.
16. Black RJ. Animal studies of prophylaxis. Am J Med. 1997;102:39-44.
17. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-1180.
18. Volmink J, Siegfried NL, van de Merwe L, et al. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2007;(1):CD003510.
19. Suksomboon N, Poolsup N, Ket-Aim S. Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection. J Clin Pharm Ther. 2007;32:293-311.
20. Kahn JO, Martin JN, Roland ME, et al. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study. J Infect Dis. 2001;183:707-714.
21. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med. 1997;337:1485-1490.
22. Young TN, Arens FJ, Kennedy GE, et al. Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure. Cochrane Database Syst Rev. 2007;24:CD002835.
23. Rapparini C. Occupational HIV infection among health care workers exposed to blood and body fluids in Brazil. Am J Infect Dis. 2006;34: 237-240.
24. Einterz RM, Kimaiyo S, Mengech HN, et al. Responding to the HIV pandemic: the power of an academic medical partnership. Acad Med. 2007;88:812-818.
25. Kenya Demographic and Health Survey 2003. Central Bureau of Statistics (CBS) [Kenya], Ministry of Health (MOH) [Kenya], and ORC Macro; 2004 Available at: http://www.measuredhs.com/pubs/pdf/FR151/FR151-KE03.pdf. Accessed March 25, 2009.
26. Hitti J, Frenkel LM, Stek AM, et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr. 2004;36:772-776.
27. US Food and Drug Administration. FDA public health advisory for nevirapine (viramune). Department of Health and Human Services. Available at: http://www.fda.gov/Cder/drug/advisory/nevirapine.htm. Accessed March 25, 2009.
28. Rey D, L'Heritier A, Lang JM. Severe ototoxicity in a health care worker who received postexposure prophylaxis with stavudine, lamivudine, and nevirapine after occupational exposure to HIV. Clin Infect Dis. 2002;34: 418-419.
29. Centers for Disease Control and Prevention. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep. 2001;50(RR-11):1-42.
30. Centers for Disease Control and Prevention. Management of possible sexual, injecting-drug-use, or other nonoccupational exposure exposure to HIV, including considerations related to antiretroviral therapy: Public Health Service statement. MMWR Recomm Rep. 1998; 47(RR-17):1-19.
31. Violence against women and children in the era of HIV and AIDS: a situational analysis and response analysis in Kenya. The global coalition on women and AIDS. Nairobi, Kenya: UNAIDS; 2006. Available at: http://data.unaids. org/pub/Report/2006/20060630-gcwa-re-violence-women-girls-kenya-en.pdf. Accessed March 25, 2009.
32. Olshen E, Hsu K, Woods ER, et al. Use of human immunodeficiency virus postexposure prophylaxis in adolescent sexual assault victims. Arch Pediatr Adolesc Med. 2006;160:754-755.
33. Garcia MT, Figueiredo RN, Moretti ML, et al. Postexposure prophylaxis after sexual assaults: a prospective cohort study. Sex Transm Dis. 2005;32: 214-219.
34. Schremmer RD, Swanson D, Kraly K. Human immunodeficiency virus postexposure prophylaxis in child and adolescent victims of sexual assault. Pediatr Emerg Care. 2005;21:502-506.
35. Meel BL. HIV/AIDS post-exposure prophylaxis (PEP) for victims of sexual assault in South Africa. Med Sci Law. 2005;45:219-224.
36. Linden JA, Oldeg P, Mehta SD, et al. HIV postexposure prophylaxis in sexual assault: current practice and patient adherence to treatment recommendations in a large urban teaching hospital. Acad Emerg Med. 2005;12:640-646.